Charles Schwab Investment Management Inc. Acquires 63,726 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Charles Schwab Investment Management Inc. grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,094,141 shares of the medical equipment provider’s stock after buying an additional 63,726 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.59% of Intuitive Surgical worth $706,479,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Baystate Wealth Management LLC increased its position in shares of Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 45 shares during the last quarter. MCF Advisors LLC lifted its stake in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 40 shares during the last quarter. Atticus Wealth Management LLC increased its stake in shares of Intuitive Surgical by 85.4% during the 4th quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 41 shares during the last quarter. MeadowBrook Investment Advisors LLC acquired a new position in Intuitive Surgical during the fourth quarter worth approximately $30,000. Finally, OFI Invest Asset Management bought a new stake in Intuitive Surgical in the third quarter valued at approximately $25,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Up 1.5 %

Shares of ISRG stock traded up $5.60 on Tuesday, reaching $388.65. The company had a trading volume of 932,774 shares, compared to its average volume of 1,608,281. The stock has a market capitalization of $137.86 billion, a PE ratio of 70.15, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39. The business’s 50-day moving average is $385.34 and its 200 day moving average is $351.97. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the previous year, the firm posted $1.00 earnings per share. The company’s revenue was up 11.5% on a year-over-year basis. On average, sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ISRG has been the subject of several research reports. Wells Fargo & Company raised their price target on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a report on Friday, January 19th. Mizuho raised their price objective on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research report on Thursday, January 25th. Raymond James upped their target price on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Citigroup boosted their price target on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, StockNews.com cut Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Robert Desantis sold 1,498 shares of the stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $369.92, for a total value of $554,140.16. Following the completion of the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 228,637 shares of company stock worth $88,483,248. 0.80% of the stock is currently owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.